Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy (NISRI)
Phase of Trial: Phase IV
Latest Information Update: 09 Mar 2017
Price : $35 *
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms NISRI
- 30 Aug 2016 Status changed from recruiting to discontinued due to poor accrual.
- 24 Feb 2016 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
- 24 Feb 2016 Planned End Date changed from 1 Mar 2016 to 1 Mar 2017 as reported by ClinicalTrials.gov.